FCA Corp’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $740K | Hold |
3,750
| – | – | 0.21% | 105 |
|
|
2025
Q4 | $689K | Hold |
3,750
| – | – | 0.19% | 109 |
|
|
2025
Q3 | $575K | Hold |
3,750
| – | – | 0.16% | 120 |
|
|
2025
Q2 | $524K | Hold |
3,750
| – | – | 0.16% | 123 |
|
|
2025
Q1 | $551K | Buy |
+3,750
| New | +$543K | 0.18% | 116 |
|
|
2024
Q4 | – | Sell |
-3,750
| Closed | -$584K | – | 184 |
|
|
2024
Q3 | $584K | Hold |
3,750
| – | – | 0.18% | 118 |
|
|
2024
Q2 | $585K | Hold |
3,750
| – | – | 0.19% | 116 |
|
|
2024
Q1 | $508K | Hold |
3,750
| – | – | 0.16% | 126 |
|
|
2023
Q4 | $505K | Hold |
3,750
| – | – | 0.17% | 124 |
|
|
2023
Q3 | $508K | Hold |
3,750
| – | – | 0.19% | 110 |
|
|
2023
Q2 | $537K | Hold |
3,750
| – | – | 0.2% | 112 |
|
|
2023
Q1 | $521K | Sell |
3,750
-250
| -6% | -$33.6K | 0.2% | 107 |
|
|
2022
Q4 | $542K | Hold |
4,000
| – | – | 0.22% | 99 |
|
|
2022
Q3 | $439K | Hold |
4,000
| – | – | 0.19% | 107 |
|
|
2022
Q2 | $529K | Hold |
4,000
| – | – | 0.21% | 99 |
|
|
2022
Q1 | $531K | Hold |
4,000
| – | – | 0.19% | 111 |
|
|
2021
Q4 | $466K | Hold |
4,000
| – | – | 0.16% | 124 |
|
|
2021
Q3 | $238K | Hold |
4,000
| – | – | 0.07% | 129 |
|
|
2021
Q2 | $479K | Hold |
4,000
| – | – | 0.14% | 123 |
|
|
2021
Q1 | $396K | Hold |
4,000
| – | – | 0.12% | 131 |
|
|
2020
Q4 | $400K | Hold |
4,000
| – | – | 0.13% | 125 |
|
|
2020
Q3 | $438K | Hold |
4,000
| – | – | 0.15% | 118 |
|
|
2020
Q2 | $423K | Hold |
4,000
| – | – | 0.16% | 103 |
|
|
2020
Q1 | $357K | Hold |
4,000
| – | – | 0.16% | 105 |
|
|
2019
Q4 | $399K | Hold |
4,000
| – | – | 0.14% | 112 |
|
|
2019
Q3 | $357K | Hold |
4,000
| – | – | 0.13% | 112 |
|
|
2019
Q2 | $330K | Hold |
4,000
| – | – | 0.12% | 116 |
|
|
2019
Q1 | $323K | Hold |
4,000
| – | – | 0.13% | 108 |
|
|
2018
Q4 | $304K | Hold |
4,000
| – | – | 0.14% | 104 |
|
|
2018
Q3 | $317K | Hold |
4,000
| – | – | 0.12% | 114 |
|
|
2018
Q2 | $281K | Hold |
4,000
| – | – | 0.11% | 118 |
|
|
2018
Q1 | $280K | Hold |
4,000
| – | – | 0.11% | 116 |
|
|
2017
Q4 | $278K | Hold |
4,000
| – | – | 0.11% | 126 |
|
|
2017
Q3 | $271K | Hold |
4,000
| – | – | 0.11% | 124 |
|
|
2017
Q2 | $273K | Hold |
4,000
| – | – | 0.12% | 114 |
|
|
2017
Q1 | $249K | Buy |
+4,000
| New | +$233K | 0.12% | 120 |
|
Other funds holding AZN
IA
VCM
VAM
FCA Corp's AZN Position: Q1 2026 in Review
FCA Corp held its AstraZeneca (AZN) position steady in Q1 2026 at 3,750 shares worth $740K. The position accounts for 0.21% of the portfolio, ranked #105.
FCA Corp first reported a position in AZN in Q1 2017 and has held it in 36 quarters since. 1,379 funds tracked by Wall St. Rank hold AZN as of Q1 2026.
- FCA Corp held 3,750 shares of AstraZeneca worth $740K as of Q1 2026.
- FCA Corp left its AstraZeneca share count unchanged in Q1 2026.
- AstraZeneca made up 0.21% of FCA Corp's portfolio in Q1 2026, its #105 holding.
- FCA Corp first reported a position in AstraZeneca in Q1 2017 and has held it in 36 quarters since.
- 1,379 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.
Based on FCA Corp's 13F filing for Q1 2026, filed 14 May 2026.